Opportunity Overview
The National Institutes of Health Office of Logistics and Acquisition Operations, supporting the National Heart, Lung, and Blood Institute, has issued Sources Sought notice 75N98026R00146 for Whole-person Assessment of Response and Risk after transformative therapies: Investigating Outcomes and Resilience in Sickle Cell Disease (WARRIOR-SCD). This is market research, not a request for proposals, and it does not commit NIH to make an award.
The notice is managed from NIH in Bethesda/Rockville, Maryland. NIH is assessing the availability and capability of qualified small businesses under NAICS 541715 for a contemplated single research effort with a potential period of approximately ten years and an anticipated award around April 2028.
Deadline and Eligibility
Capability statements must be received by October 2, 2026 at 3:00 PM Eastern Standard Time (EST), using the time-zone wording published in the Sources Sought document. The notice is specifically for interested small businesses. Respondents must identify their size classification under NAICS 541715; small-business status must be certified by the Small Business Administration. Organizations that are not small under NAICS 541715 should not respond. Applicable HUBZone, SDVOSB, 8(a), VOSB, WOSB and small-disadvantaged classifications may also be identified.
Anticipated Scope
The contemplated program is a multicenter long-term clinical research effort involving people with sickle cell disease who have received gene therapy or hematopoietic cell transplantation. Current solicitation-derived materials describe approximately 700 participants enrolled over five years with annual longitudinal follow-up that may extend for 15 years or longer subject to funding and program direction. Required capabilities include study design and procedures, program and site management, participant enrollment and retention, clinical and patient-reported outcomes data collection, data management and statistical analysis, biospecimen coordination and testing support, data-quality monitoring, privacy and security compliance, ancillary-study support, dissemination of findings, and provision of shareable datasets and biospecimens.
Capability Statement
Respondents must provide a complete and sufficiently detailed capability statement addressing each project requirement, organizational staffing and qualifications, facilities and equipment, relevant prior research projects and other information necessary for NIH to assess capability. Current solicitation-derived materials state a limit of 15 single-sided pages or 7.5 double-sided pages, using at least 12-point font. The response must identify the respondent’s applicable small-business size standard and a knowledgeable point of contact.
Submission is by email to Contracting Officer Elizabeth Bulger and Contract Specialist Jessica Williams, with Sources Sought notice number 75N98026R00146 in the subject line. The notice instructs respondents not to include proprietary, classified, confidential or sensitive information. A Sources Sought response will not substitute for any later solicitation response.
Funding, Cost Share, Forms and Amendments
No contract ceiling, guaranteed value or current award amount is published. This is a federal procurement-market-research notice, not a grant, so no non-Federal match or grant cost share is stated. One source document, CureSCI_Sought_Notice_Warrior_1.pdf, is identified. Current notice history shows one Sources Sought posting and no amendment. No separate application forms or FAQ package is identified in the materials reviewed by Atlas.
Atlas Analysis
Atlas Opportunity Score: 86/100. The contemplated work is a substantial, long-horizon NIH clinical research program with clear Maryland acquisition management and meaningful small-business capture value, although this Sources Sought stage does not itself create an award opportunity.
N9+ Fit Score: 0/100. The verified requirement centers on multicenter sickle-cell clinical research, longitudinal outcomes, biospecimens, data management and study operations. It does not establish remote physical-examination hardware or telehealth platform acquisition as a requirement, so Atlas will not force an N9+ fit.
QC Healthcare / Dr. Miltie Fit: 5/100 conditional. Dr. Miltie, LLC is NOT CLEARED / No Bid as a direct respondent on currently verified evidence. Atlas has not verified SBA-certified small-business eligibility under NAICS 541715, the required long-term multicenter sickle-cell research experience, qualifying scientific/clinical personnel, research-site management, biospecimen operations, statistical/data-management infrastructure, or comparable prior projects. None of those qualifications should be inferred or fabricated.
Required Next Action
Monitor SAM.gov for revisions or a resulting solicitation. A direct Dr. Miltie response should proceed only if every applicant-controlled small-business, scientific, clinical-research, staffing, facility, data-management, biospecimen and past-project qualification is independently verified.
Official source: SAM.gov — 75N98026R00146.
Last verified September 11, 2026.